Dapansutrile

Generic Name
Dapansutrile
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C4H7NO2S
CAS Number
54863-37-5
Unique Ingredient Identifier
2Z03364G96
Background

Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

Phase 2
Recruiting
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Dapansutrile
Drug: Placebo
First Posted Date
2023-09-21
Last Posted Date
2024-08-14
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
300
Registration Number
NCT06047262
Locations
๐Ÿ‡จ๐Ÿ‡ญ

University Hospital Basel, Basel, Switzerland

Advanced Cardiovascular Imaging of the Systemic Effects of Inflammasome Activation

Early Phase 1
Not yet recruiting
Conditions
Myocardial Infarction
Interventions
Other: Placebo
Drug: Dapansutrile
First Posted Date
2023-05-30
Last Posted Date
2023-10-02
Lead Sponsor
University of Virginia
Target Recruit Count
60
Registration Number
NCT05880355
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Virginia, Charlottesville, Virginia, United States

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

First Posted Date
2022-12-20
Last Posted Date
2024-12-04
Lead Sponsor
Olatec Therapeutics LLC
Target Recruit Count
300
Registration Number
NCT05658575
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Alabama at Birmingham, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Arizona Arthritis & Rheumatology Associates - Glendale, Glendale, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

Arizona Arthritis & Rheumatology Associates (AARA), P.C. - Mesa, Mesa, Arizona, United States

and more 30 locations

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

Phase 1
Recruiting
Conditions
Melanoma
Interventions
Drug: Dapansutrile
Drug: Pembrolizumab
First Posted Date
2021-07-21
Last Posted Date
2024-05-30
Lead Sponsor
April Salama, M.D.
Target Recruit Count
26
Registration Number
NCT04971499
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Duke Cancer Center, Durham, North Carolina, United States

Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome

Phase 2
Terminated
Conditions
Schnitzler Syndrome
Interventions
Drug: dapansutrile
First Posted Date
2018-07-23
Last Posted Date
2024-02-02
Lead Sponsor
Olatec Therapeutics LLC
Target Recruit Count
2
Registration Number
NCT03595371
Locations
๐Ÿ‡ณ๐Ÿ‡ฑ

Radboudumc, Nijmegen, Netherlands

ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy